Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091852 | 0.93 | KDM4E (0.36) | TP53MAPTSMN1; SMN2POLBKDM4E | |
| SCHEMBL4097169 | 0.90 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL4090997 | 0.89 | KDM4E (0.36) | TP53MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4103520 | 0.88 | KDM4E (0.39) | TP53MAPTKDM4EALDH1A1GAA | |
| SCHEMBL4090920 | 0.83 | KDM4E (0.36) | MAPTSMN1; SMN2KDM4EALDH1A1CHEK1 | |
| SCHEMBL4105720 | 0.82 | KDM4E (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1GAA | |
| Citric Acid SCHEMBL4109472 | 0.81 | KDM4E (0.38) | TP53MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4099405 | 0.78 | HTR2A (0.35) | TP53MAPTKDM4EALDH1A1TDP1 | |
| SCHEMBL5242696 | 0.74 | HTR1B (0.41) | KDM4E | |
| SCHEMBL4044879 | 0.74 | GAA (0.46) | TP53MAPTSMN1; SMN2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221687-A1 | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2009-09-03 | — | — | US | claimed |
| US-20090221687-A1 | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221687-A1 | Tetracyclic Monoamine Reuptake Inhibitors for Treatment of Cns Diseases and Disorders | MAOB, MAOA, TPH1 | TP53 4885/4885MAPT 102/4885SMN1; SMN2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.